English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Whole brain radiotherapy (WBRT) has traditionally been the standard treatment for brain metastases [1]. More recently, patients with limited brain metastases are being offered stereotactic radiosurgery (SRS), with or without WBRT, in an attempt to improve survival and functional outcomes. A recent editorial has suggested that the sun is setting on WBRT and SRS is rising to be the standard of care [2]. This editorial summarizes the data from individual international randomized trials and a meta-analysis regarding the role of SRS in patients with limited brain metastases, and will focus on its role as a definitive therapy. For patients with limited brain metastases, definitive local therapy in addition to WBRT has been demonstrated to improve local control and overall survival compared with WBRT alone [3–5]. In the Radiation Therapy Oncology Group (RTOG) 9508 trial, patients with 1–3 new brain metastases were randomized to WBRT alone or WBRT plus SRS. A survival advantage was observed in patients with a single brain metastasis who were treated with WBRT plus SRS [5]. Furthermore, the addition of SRS resulted in significant improvements in local tumor control, Karnofsky Performance Status (KPS) and reducing steroid dependency and did not increase acute or late toxicities [5]. Reinforcement of the importance of local control for brain metastasis patients was provided by two Phase III trials comparing WBRT with or without surgical resection in patients with solitary metastases [3,4]. In these studies, both local control and survival were improved by more aggressive local therapy. Interestingly and importantly, a trial comparing resection with or without WBRT showed no survival advantage to the addition of WBRT, even though decreased distant brain failures were observed [6]. This result likely reflects both the efficacy of SRS and WBRT as salvage therapies and the competing risk of extracranial disease

Stereotactic radiosurgery alone for limited brain metastases: are we ready for prime time?